Suppr超能文献

多重靶向 CRISPR-Cas9 保护 T 细胞免受急性 HIV-1 感染,抑制病毒逃逸。

Multiplexed -Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape.

机构信息

Division of Molecular Medicine and Medical Genetics, Department of Pathology, Kobe University Graduate School of Medicine, Kobe 650-0017 Hyogo, Japan.

Division of Global Infectious Diseases, Department of Public Health, Kobe University Graduate School of Health Sciences, Kobe 654-0142 Hyogo, Japan.

出版信息

Viruses. 2020 Oct 28;12(11):1223. doi: 10.3390/v12111223.

Abstract

HIV-1 cure strategy by means of proviral knock-out using CRISPR-Cas9 has been hampered by the emergence of viral resistance against the targeting guide RNA (gRNA). Here, we proposed multiple, concentrated gRNA attacks against HIV-1 regulatory genes to block viral escape. The T cell line were transduced with single and multiple gRNAs targeting HIV-1 and using lentiviral-based CRISPR-Cas9, followed by replicative HIV-1 challenge in vitro. Viral p24 rebound was observed for almost all gRNAs, but multiplexing three -targeting gRNAs maintained p24 suppression and cell viability, indicating the inhibition of viral escape. Multiplexed gRNAs inhibited acute viral replication in the 2nd round of infection, abolished cell-associated transmission to unprotected T cells, and maintained protection through 45 days, post-infection (dpi) after a higher dose of HIV-1 infection. Finally, we describe here for the first time the assembly of all-in-one lentiviral vectors containing three and six gRNAs targeting and . A single-vector -targeting construct shows non-inferiority to the -targeting multi-vector in low-dose HIV-1 infection. We conclude that Cas9-induced, DNA repair-mediated mutations in are sufficiently deleterious and deplete HIV-1 fitness, and multiplexed disruption of further limits the possibility of an escape mutant arising, thus elevating the potential of CRISPR-Cas9 to achieve a long-term HIV-1 cure.

摘要

使用 CRISPR-Cas9 进行前病毒敲除的 HIV-1 治愈策略受到针对靶向向导 RNA(gRNA)的病毒耐药性的出现的阻碍。在这里,我们提出了针对 HIV-1 调节基因的多个集中的 gRNA 攻击,以阻止病毒逃逸。使用基于慢病毒的 CRISPR-Cas9 将 T 细胞系转导到靶向 HIV-1 和 的单个和多个 gRNA 中,然后进行体外复制性 HIV-1 挑战。几乎所有 gRNA 都观察到病毒 p24 反弹,但靶向三个 gRNA 的多重化保持了 p24 抑制和细胞活力,表明抑制了病毒逃逸。多重 gRNA 抑制了第二轮感染中的急性病毒复制,消除了对未受保护的 T 细胞的细胞相关传播,并在感染后 45 天(dpi)保持保护,在更高剂量的 HIV-1 感染后。最后,我们在这里首次描述了包含靶向 和 的三个和六个 gRNA 的一体式慢病毒载体的组装。针对单-载体的构建在低剂量 HIV-1 感染中显示出与靶向多载体的非劣效性。我们得出结论,Cas9 诱导的 DNA 修复介导的 中的突变是足够有害的,并耗尽了 HIV-1 的适应性,并且靶向多个 gRNA 的破坏进一步限制了逃逸突变体出现的可能性,从而提高了 CRISPR-Cas9 实现长期 HIV-1 治愈的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3507/7693572/09e0b2a7ad49/viruses-12-01223-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验